Auro Laboratories

Auro Laboratories Forward P/E

The Forward P/E Ratio of Auro Laboratories (530233.BO) as of Oct 17, 2026 is 48.19. In the previous year, Forward P/E Ratio was 92.59 — a change of -47.95% (lower).

Forward P/E

48.19

YoY

-47.95%

Last updated:

Forward P/E Ratio of Auro Laboratories is 2026 48.19 . Forward P/E Ratio of Auro Laboratories was 2025 92.59 . It decreases by -47.95% lower compared to the previous year.

The Auro Laboratories Forward P/E history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Forward P/E
Date
Forward P/E
Jan 1, 2019
38.70 INR
Jan 1, 2020
41.99 INR
Jan 1, 2021
23.71 INR
Jan 1, 2022
59.85 INR
Jan 1, 2023
69.71 INR
Jan 1, 2024
21.85 INR
Jan 1, 2025
92.59 INR
Jan 1, 2026
48.19 INR
The Auro Laboratories Forward P/E history
YEARForward P/EYoY
48.19-47.95%
92.59+323.76%
21.85-68.66%
69.71+16.49%
59.85+152.39%
23.71-43.53%
41.99+8.51%
38.70-19.77%
48.24-76.90%
208.85+8.18%
193.05-8.85%
211.80-27.97%
294.04—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Auro Laboratories Stock analysis

What does Auro Laboratories do? Auro Laboratories Ltd is a pharmaceutical company headquartered in Mumbai, India. The company engages in the manufacture of active pharmaceutical ingredients (APIs), intermediates, and generic formulations. It operates primarily within the Pharmaceuticals sector. Auro Laboratories offers APIs across various therapeutic categories, including antihistamines, muscle relaxants, diuretics, iron deficiency treatments, anti-diabetics, anti-fungals, anti-ulcer medications, iodine supplements, anti-malarials, analgesics, antacids, and anti-inflammatories. The company also produces intermediates such as Glibenclamide Sulphonamide, Cis-bromo benzoate, Cls-Tosylate, 2-Ethoxy Benzoic Acid, 3,4,5-Trimethoxy Benzoic Acid, and 5-Bromo Phthalide. Additionally, Auro Laboratories provides toll and custom manufacturing services for APIs and intermediates on a contract basis. The company has an international presence, with a significant portion of its production exported to Southeast Asia, the Middle East, and various European countries. Key export destinations include Egypt, Germany, Malaysia, Singapore, South Africa, Brazil, Spain, and the United Kingdom. Auro Laboratories went public with its IPO on March 7, 1995. The company's website is http://www.aurolabs.com/. Auro Laboratories is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Auro Laboratories stock

Forward P/E Ratio of Auro Laboratories is 48.19 in 2026.

Forward P/E Ratio of Auro Laboratories changed from 92.59 to 48.19, representing a -47.95% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Forward P/E Ratio Auro Laboratories since 2006 – with annual values, charts, and detailed analysis.

The Forward P/E uses estimated future earnings to value a stock. A lower forward P/E relative to the trailing P/E suggests analysts expect earnings growth.

To evaluate Forward P/E Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Forward P/E Ratio.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Forward P/E Ratio's Auro Laboratories with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Auro Laboratories

All Key Metrics — Auro Laboratories